Literature DB >> 22632361

Evaluating Graves' orbitopathy.

Peter J Dolman1.   

Abstract

Graves' Orbitopathy (GO) is an immune-mediated disorder causing inflammation and expansion of orbital fat and muscle. The resulting spectrum of ocular and orbital changes may cause significant visual and cosmetic morbidity and are graded as disease severity. The disease follows a biphasic course with an active or progressive phase followed by a quiescent or stable phase: the temporal status is graded as disease activity. Grading systems for GO include Werner's NO SPECS and European Group on Graves' Orbitopathy (EUGOGO)'s severity scales, the Clinical Activity Score (CAS) and the VISA Classification (for severity and activity). Diagnosis of GO is based on recognition of clinical features and may be supported by thyroid function and immune testing, and orbital imaging. The endocrinologist or internist may play an important role in early recognition and diagnosis of GO, in grading severity and activity, and in arranging appropriate referral to an ophthalmologist based on this evaluation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22632361     DOI: 10.1016/j.beem.2011.11.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  27 in total

1.  Graves' disease syndrome: a need for unified therapy.

Authors:  Rebecca S Bahn
Journal:  J Transl Int Med       Date:  2016-07-07

2.  Preoperative clinical features of reactivated of Graves' orbitopathy after orbital decompression.

Authors:  Y J Woo; J W Kim; J S Yoon
Journal:  Eye (Lond)       Date:  2017-01-06       Impact factor: 3.775

Review 3.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

4.  99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy.

Authors:  B Sun; Z Zhang; C Dong; Y Zhang; C Yan; S Li
Journal:  Eye (Lond)       Date:  2017-04-07       Impact factor: 3.775

5.  Chromatic visual evoked potentials identify optic nerve dysfunction in patients with Graves' orbitopathy.

Authors:  Yueqi Yu; Bingjie Shi; Shengnan Cheng; Yushuai Liu; Ru Zhu; Yayan You; Jin Chen; Xiaohuan Pi; Xinghua Wang; Fagang Jiang
Journal:  Int Ophthalmol       Date:  2022-05-30       Impact factor: 2.031

Review 6.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

7.  99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves' ophthalmopathy patients.

Authors:  Dan Liu; Xueliang Xu; Sha Wang; Chengzhi Jiang; Xinhui Li; Jia Tan; Zhihong Deng
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

8.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

Review 9.  Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.

Authors:  M Marinò; I Ionni; G Lanzolla; A Sframeli; F Latrofa; R Rocchi; C Marcocci
Journal:  J Endocrinol Invest       Date:  2019-11-05       Impact factor: 5.467

10.  Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy.

Authors:  Yue-Yue Wang; Qian Wu; Lu Chen; Wen Chen; Tao Yang; Xiao-Quan Xu; Fei-Yun Wu; Hao Hu; Huan-Huan Chen
Journal:  Endocr Connect       Date:  2021-06-24       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.